LGND - Company ID 0000886163
LIGAND PHARMACEUTICALS INC (LGND) reported revenue of $268.09M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $268.09M | +60.4% |
| FY 2024 | $167.13M | +27.3% |
| FY 2023 | $131.31M | -33.1% |
| FY 2022 | $196.25M | -18.8% |
| FY 2021 | $241.54M | +47.7% |
| FY 2020 | $163.56M | +36.0% |
| FY 2019 | $120.28M | -52.2% |
| FY 2018 | $251.45M | +78.2% |
| FY 2017 |
LIGAND PHARMACEUTICALS INC (LGND) reported revenue of $268.09M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, LIGAND PHARMACEUTICALS INC's revenue grew from $30.04M to $268.09M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $141.10M |
| +29.5% |
| FY 2016 | $108.97M | +51.5% |
| FY 2015 | $71.91M | +11.4% |
| FY 2014 | $64.54M | +31.8% |
| FY 2013 | $48.97M | +56.0% |
| FY 2012 | $31.39M | +4.5% |
| FY 2011 | $30.04M | - |